Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Leblanc

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer|August 21, 2004
ProteomicsDavid M Naistat, Roger Leblanc
Chemistry (Weinheim an Der Bergstrasse, Germany)|November 18, 2017
The Investigation on Resorcinarenes towards either Inhibiting or Promoting Insulin FibrillationXu Han, Chuan Tian, Ingrid Gandra, et al.
Biophysical Chemistry|September 12, 2002
ZL-DHP lignin model compound at the air-water interfaceMiodrag Micic, Jhony Orbulescu, Ksenija Radotic, et al.
The Analyst|April 15, 2011
Determination of the size of quantum dots by fluorescence spectroscopyDragosav Mutavdžić, Jianmin Xu, Garima Thakur, et al.
AIDS (London, England)|April 26, 2011
Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoireMatthew S Parsons, Danielle Rouleau, Jean-Pierre Routy, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 10, 2020
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19Fabio Rocha Formiga, Roger Leblanc, Juliana de Souza Rebouças, et al.
HIV Clinical Trials|June 29, 2005
Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patientsGraham H R Smith, Mohamed-Rachid Boulassel, Marina Klien, et al.
HIV Research & Clinical Practice|September 20, 2019
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 studyMiranda Murray, Federico Pulido, Anthony Mills, et al.
AIDS (London, England)|April 6, 2016
The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infectionVikram Mehraj, Mohammad-Ali Jenabian, Rosalie Ponte, et al.
Open Forum Infectious Diseases|March 30, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of StudyKenneth C Sutton, Jerome De Vente, Roger Leblanc, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer|August 21, 2004
ProteomicsDavid M Naistat, Roger Leblanc
Chemistry (Weinheim an Der Bergstrasse, Germany)|November 18, 2017
The Investigation on Resorcinarenes towards either Inhibiting or Promoting Insulin FibrillationXu Han, Chuan Tian, Ingrid Gandra, et al.
Biophysical Chemistry|September 12, 2002
ZL-DHP lignin model compound at the air-water interfaceMiodrag Micic, Jhony Orbulescu, Ksenija Radotic, et al.
The Analyst|April 15, 2011
Determination of the size of quantum dots by fluorescence spectroscopyDragosav Mutavdžić, Jianmin Xu, Garima Thakur, et al.
AIDS (London, England)|April 26, 2011
Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoireMatthew S Parsons, Danielle Rouleau, Jean-Pierre Routy, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 10, 2020
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19Fabio Rocha Formiga, Roger Leblanc, Juliana de Souza Rebouças, et al.
HIV Clinical Trials|June 29, 2005
Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patientsGraham H R Smith, Mohamed-Rachid Boulassel, Marina Klien, et al.
HIV Research & Clinical Practice|September 20, 2019
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 studyMiranda Murray, Federico Pulido, Anthony Mills, et al.
AIDS (London, England)|April 6, 2016
The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infectionVikram Mehraj, Mohammad-Ali Jenabian, Rosalie Ponte, et al.
Open Forum Infectious Diseases|March 30, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of StudyKenneth C Sutton, Jerome De Vente, Roger Leblanc, et al.
Pageof 4